Transfection News and Research

RSS

Adeno-associated virus: The gene therapy revolution faces manufacturing and safety hurdles

Recombinant adeno-associated virus (rAAV)-based genetic applications to treat human diseases.

5 Apr 2024

Focusing on oncogenic driver mutations and resistance mechanisms in the treatment of NSCLC

Lung cancer is the leading cause of cancer-related death worldwide. Improved understanding of driver mutations of non-small cell lung cancer (NSCLC) has led to more biomarker-directed treatment for patients with advanced stages.

26 Mar 2024

Developing mRNA lipid nanoparticles for treating oral squamous cell carcinoma

A study aiming to develop a Lipid nanoparticles (LNP) platform for treating oral squamous cell carcinoma (OSCC) utilizing p53 mRNA was presented at the 102nd General Session of the IADR, which was held in conjunction with the 53rd Annual Meeting of the American Association for Dental, Oral, and Craniofacial Research and the 48th Annual Meeting of the Canadian Association for Dental Research, on March 13-16, 2024, in New Orleans, LA, USA.

19 Mar 2024

Asimov launches LV Edge Packaging System to optimize lentivirus production

New off-the-shelf system reduces the cost and risk of lentiviral (LV) production for cell and gene therapy developers.

From Asimov 29 Jan 2024

New vaccine strategy targets SARS-CoV-2's stable S2 subunit, offering broad protection against evolving variants

Study presents a new SARS-CoV-2 S2 subunit vaccine that elicits strong antibody responses against various sarbecovirus strains, including challenging variants like XBB.1.5, demonstrating its potential as a broadly effective and stable vaccine option.

18 Dec 2023

MIT scientists develop nanoparticles to reduce inflammation in the brain

Some Covid-19 vaccines safely and effectively used lipid nanoparticles (LNPs) to deliver messenger RNA to cells. A new MIT study shows that different nanoparticles could be used for a potential Alzheimer's disease (AD) therapy.

11 Dec 2023

Small molecule applications of process Raman spectroscopy

In this interview, Kevin Broadbelt of Thermo Fisher Scientific discusses the small molecule applications of process Raman spectroscopy.

From Thermo Fisher Scientific – Portable and Handheld Raman Spectroscopy 11 Dec 2023

Researchers discover next-gen lipid nanoparticles for muscle-focused mRNA delivery

A team of researchers based at the University of Toronto's (U of T) Leslie Dan Faculty of Pharmacy has discovered a novel ionizable lipid nanoparticle that enables muscle-focused mRNA delivery while minimizing off-target delivery to other tissues.

8 Dec 2023

A step forward in vaccine technology: Exploring the effects of N1-methylpseudouridine in mRNA translation

Researchers explored how the incorporation of N1-methylpseudouridine (1-methylΨ) into mRNAs affects ribosomal frameshifting and the overall fidelity of mRNA translation.

7 Dec 2023

Novel mRNA vaccine GLB-COV2-043 shows high efficacy against COVID-19 variants in early trials

The safety, efficacy, and immunogenicity of a mRNA-based vaccine.

5 Dec 2023

Novel miRNA-based therapy shows promise for treatment of drug-resistant biliary tract cancer

Biliary tract cancers (BTCs) including cholangiocarcinoma (CCA) and gallbladder cancer (GBC) are becoming more prevalent globally.

30 Nov 2023

Empowering oncology research: Transmembrane proteins and cutting-edge production platforms

In this Interview, Dr. Fang-Yi Chu talks to NewsMed about the role of transmembrane proteins in targeting oncology research.

From Sino Biological Inc. 23 Nov 2023

MaxCyte joins the alliance for mRNA medicines (AMM) as a founding member

MaxCyte, Inc. today announced that it has joined the Alliance for mRNA Medicines, as a founding member.

From MaxCyte, Inc. 22 Nov 2023

Breakthrough in HIV treatment: NMN shows promise in reducing CD4+ T cell activation

The impact of nicotinamide mononucleotide (NMN) on Clusters of differentiation 4+ (CD4+ ) Thymus cells (T cells) viz.

21 Nov 2023

MaxCyte joins the Alliance for mRNA Medicines (AMM) as a founding member

MaxCyte, Inc., a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell-based therapeutics and innovative bioprocessing applications, today announced that it has joined the Alliance for mRNA Medicines (AMM), as a founding member.

From MaxCyte, Inc. 16 Nov 2023

Genetically edited chickens show resistance to avian influenza in landmark study

Researchers use CRISPR technology to create chickens resistant to avian influenza, targeting specific genes to inhibit viral replication. The study reveals both the promise and complexities of using genetic editing as a disease control strategy, also shedding light on influenza's adaptability.

11 Oct 2023

Recent Advancements in Cell Based Therapy

In this interview, NewsMedical talks to James Brady about cell-based therapy and how the field of genetic engineering transformed.

From MaxCyte, Inc. 11 Oct 2023

Innovations in baculovirus–insect cell expression systems

The baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)— remains a crucial technology for manufacturing large and complex proteins. This eukaryotic expression system offers inherent safety, ease of scale-up, flexible product design, and versatility for a broad range of proteins.

From Sino Biological Inc. 20 Sep 2023

How well do current vaccines hold up against new SARS-CoV-2 variants BA.2.86 and FLip?

The study explores the efficacy of three-dose monovalent or bivalent vaccinations in neutralizing newly emerged SARS-CoV-2 variants BA.2.86 and FLip. While BA.2.86 showed lower immune evasion abilities compared to recent XBB variants, it was less effectively neutralized by the monoclonal antibody S309, raising questions about vaccine efficacy against evolving strains.

17 Sep 2023

New way to administer CAR-T-cell therapy could lead to fewer side effects

When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.

8 Sep 2023